We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

International T1 Multicentre CMR Outcome Study (T1-CMR)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02407197
Recruitment Status : Completed
First Posted : April 2, 2015
Last Update Posted : March 9, 2023
Information provided by (Responsible Party):
Eike Nagel, King's College London

Brief Summary:

Myocardial fibrosis is the fundamental substrate for the development of heart failure.

Cardiovascular magnetic resonance (CMR) allows non-invasive assessment of myocardial fibrosis based on late gadolinium enhancement (LGE) and T1 mapping.

Patients: Prospective longitudinal observational multicenter study of consecutive patients with suspected or known non-ischemic cardiomyopathy.

Imaging: Non-invasive measures of myocardial fibrosis: native T1, extracellular volume fraction (ECV) and LGE.

Primary endpoints: all cause and cardiovascular mortality.

Secondary endpoints: arrhythmic composite and HF composite endpoints.

Condition or disease
Cardiomyopathy Heart Failure Coronary Artery Disease Chronic Kidney Diseases Inflammation Fibrosis

Layout table for study information
Study Type : Observational [Patient Registry]
Actual Enrollment : 1629 participants
Observational Model: Cohort
Time Perspective: Prospective
Target Follow-Up Duration: 5 Years
Official Title: International T1 Multicentre CMR Study
Actual Study Start Date : January 2011
Actual Primary Completion Date : December 2017
Actual Study Completion Date : December 1, 2022

Resource links provided by the National Library of Medicine

Primary Outcome Measures :
  1. Survival [ Time Frame: 1 year ]
    number of deaths

Secondary Outcome Measures :
  1. Rate of Arrhythmia [ Time Frame: 1 year ]
    number of fatal or aborted sudden cardiac death events (including a documented appropriate shock from ICD)

  2. Rate of HF events [ Time Frame: 1 year ]
    Number of HF death and unplanned HF hospitalization

  3. Rate of deaths due to cardiovascular causes [ Time Frame: 1 year ]
    Number of composite of sudden cardiac death (SCD), death from HF, death from stroke or thromboembolic event

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
adult population with clinically indicated CMR study

Inclusion Criteria:

  1. adults > 18 years of age
  2. clinical indication for CMR
  3. able to provide informed consent

Exclusion criteria:

contraindications for cardiac magnetic resonance imaging due to MR unsafe devices or objects

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02407197

Layout table for location information
Australia, New South Wales
Vincent's University
Sydney, New South Wales, Australia, NSW 2010
German Heart Institute Berlin
Berlin, Germany, 13353
United Kingdom
Guy's and St. Thomas' Hospital Trust
London, United Kingdom, SE1 7EH
King's College Hospital
London, United Kingdom, SE5 9RS
Sponsors and Collaborators
King's College London
Layout table for investigator information
Principal Investigator: Eike Nagel, MD, PhD King's College London
Additional Information:
Publications of Results:

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Eike Nagel, Global Chief Investigator, King's College London
ClinicalTrials.gov Identifier: NCT02407197    
Other Study ID Numbers: 2011-T1-MC
First Posted: April 2, 2015    Key Record Dates
Last Update Posted: March 9, 2023
Last Verified: March 2023
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Eike Nagel, King's College London:
T1 mapping
Additional relevant MeSH terms:
Layout table for MeSH terms
Kidney Diseases
Renal Insufficiency, Chronic
Coronary Artery Disease
Heart Diseases
Cardiovascular Diseases
Pathologic Processes
Urologic Diseases
Coronary Disease
Myocardial Ischemia
Arterial Occlusive Diseases
Vascular Diseases
Renal Insufficiency